{"id":"NCT02346721","sponsor":"Gilead Sciences","briefTitle":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection","officialTitle":"An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-23","primaryCompletion":"2016-03-23","completion":"2016-06-15","firstPosted":"2015-01-27","resultsPosted":"2017-05-03","lastUpdate":"2018-11-16"},"enrollment":111,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["GS-7977/GS-5816","EpclusaÂ®"]}],"arms":[{"label":"SOF/VEL","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) in participants with chronic genotype 1, 2, 4, 6 or indeterminate HCV infection who received placebo in the Gilead-sponsored study GS-US-342-1138.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL 12 Weeks","deltaMin":97.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":61,"countries":["United States","Belgium","Canada","France","Germany","Hong Kong","Italy","Puerto Rico","United Kingdom"]},"refs":{"pmids":["31216086"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":111},"commonTop":["Headache","Fatigue","Nausea","Diarrhoea","Cough"]}}